Skip to main content
Premium Trial:

Request an Annual Quote

Haines Named CEO of Whatman; Linnarsson, Ernfors to Join Genizon; Watson Named CEO, Baunoch COO, of CombiMatrix Molecular Dx Unit; and More

Timothy Haines has been named chief executive officer of Whatman, effective Sept. 1, the company said last week. He will join the company from Astex Technology, where he is CEO. Haines holds a BSc from Exeter University in the UK and an MBA from INSEAD. Haines will replace Tom McNally, who has held executive responsibilities at Whatman since January, when the company started to search for a new CEO. In 2006, McNally will return to his position as non-executive director of Whatman.

Following the acquisition of Swedish firm Global Genomics by Montreal-based Genizon BioSciences, Global co-founders Sten Linnarsson and Patrik Ernfors will join Genizon, the company said today.

Matthew Watson will be chief executive officer, and David Baunoch president and chief operating officer of CombiMatrix Molecular Diagnostics, a new subsidiary of CombiMatrix, the company said yesterday. Both come to CMD from US Labs, where Watson was vice president of laboratory operations and Baunoch vice president of research and development. US Labs was recently acquired by Laboratory Corporation of America. Watson holds a BS in biology from Eastern Connecticut State University and an MBA from the University of Hartford. Baunoch has a PhD in microbiology and molecular genetics from Wayne State University.

Susan Vogt, president of Millipore's BioPharmaceutical division, will be leaving the company on May 27 "to pursue other interests," Millipore said today. CEO Martin Madaus will lead the division until the company has found a successor.

Tony Lima has become vice president of sales at Velocity11, the Menlo Park, Calif.-based company said today. Most recently, Lima was chief operating officer at DiscoveRx. Before that, he was vice president of worldwide sales and service at Molecular Devices.

Michael Pellini has become chief operating officer of Lakewood Pathology Associates, the New Jersey-based company said on Monday. He joins Lakewood from Genomics Collaborative, where he was CEO until its acquisition by SeraCare Life Sciences. After that, he worked as "Entrepreneur-in-Residence" at BioAdvance of Pennsylvania. Pellini holds a medical degree from the Jefferson Medical College of Thomas Jefferson University and an MBA from DrexelUniversity.

Alex Kotzer will become president and chief executive officer of Compugen, starting in September, the Tel Aviv-based company said yesterday. Most recently, he was vice president at Serono of Geneva. Kotzer will replace president and CEO Mor Amitai, who said in October that he intended to resign before the end of 2005. Kotzer holds a BSc in chemical engineering from the Technion in Haifa, Israel.

Rosanne Coppola and Bruce Koepfgen have joined the board of directors of Fisher Scientific, the company said last week. Coppola is a director of M&F Worldwide, and Koepfgen is chief executive officer of Oppenheimer Capital.

David Galas has become vice president and chief scientific officer for biological and life sciences of Batelle, the Columbus, Ohio-based research organization said last week. In the past, Galas was chancellor, chief scientific officer, and professor of applied life sciences at the Keck Graduate Institute of Life Sciences in Claremont, California. He was also among the early leaders in the US Human Genome Program and, from 1990 to 1993, led the US Department of Energy's component of this project. Galas holds MS and PhD degrees in physics from the University of California, Davis-Livermore, and an AB in physics from the University of California, Berkeley.

Akubio, has appointed Jerry Walker as its new chief executive officer, the acoustic biosensor technology company said today. Walker recently served as European president of GE Healthcare, and previously held various senior administrative positions at Amersham Biosciences before it was acquired by GE. He holds a PhD in biochemistry.


Akubio has also named Jonathan Glenn as chief financial officer.

Glenn previously served as global head of finance at Celltech and CFO of Oxford GlycoSciences .

Bernd Aundrup and Johann Löhn have resigned from their positions in MWG Biotech's Supervisory Board following the company's annual meeting, the company said yesterday.


Taking their seats will be Gilles Martin, the chief executive officer of Nantes, France-based Eurofins Scientifics and Matthias-Wilbur Weber, Eurofins' chief financial officer.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.